Long-term outcomes of drug-coated balloons vs. drug-eluting stents in coronary chronic total occlusion angioplasty: the SPARTAN-CTO study
Clinical Research in Cardiology · 12.02.2026
DOI: 10.1007/s00392-026-02852-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Research in Cardiology, online erschienen am 12.02.2026. Verfasst von Rajkumar Natarajan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Norwich University Hospital, Norfolkand, UK. r.natarajan@uea.ac.uk. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim
The role of drug-coated balloon (DCB)–only strategy in de novo chronic total occlusion (CTO) percutaneous coronary intervention (PCI) remains uncertain. We compared DCB with drug-eluting stent (DES) strategies in patients undergoing CTO angioplasty.
Methods
We retrospectively analyzed 170 patients with de novo CTO undergoing PCI between 2013 and 2019. Patients were treated with either DCB-only ( n = 85) or DES-only ( n = 85) strategies. The primary endpoint was target vessel revascularization (TVR); secondary endpoints included all-cause mortality, cardiovascular death, target vessel-myocardial infarction (TV-MI), any MI, and a composite of all-cause mortality, MI, and TVR. Median follow-up was 3.67 years.
Results
TVR occurred in 11 (12.9%) DCB vs. 5 (5.9%) DES patients (HR 2.33, 95% CI 0.81–6.74, p = 0.118). All-cause mortality (7.1% vs. 12.9%; HR 0.56, p = 0.262) and the composite endpoint (21.2% vs. 20.0%; HR 1.15, p = 0.686) did not differ significantly. After adjustment for creatinine, J-CTO score, and vessel diameter, outcomes remained comparable between groups. Creatinine was independently associated with mortality and the composite endpoint. No acute vessel closure or thrombosis occurred within 30 days. During follow-up, no target lesion thrombosis was observed in the DCB group, while one late stent thrombosis (1.2%) occurred in the DES group.
Conclusion
In this single-center study, a DCB-only strategy for de novo CTO PCI demonstrated long-term efficacy and safety outcomes comparable to DES, supporting DCB as a potential alternative. Graphical Abstract
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Norwich University Hospital, Norfolkand, UK. r.natarajan@uea.ac.uk.
- Norwich Medical School, University of East Anglia, 2.06 Bob Champion Research & Education Building, Norwich, NR4 7TJ, UK. r.natarajan@uea.ac.uk.
- Department of Cardiology, Norwich University Hospital, Norfolkand, UK.
- Norwich Medical School, University of East Anglia, 2.06 Bob Champion Research & Education Building, Norwich, NR4 7TJ, UK.
Zitieren
APA
Natarajan, R., Corballis, N., Merinopoulos, I., Gunawardena, T., Wickramarachchi, U., Clark, A., Vassiliou, V. S., Eccleshall, S. C., & SPARTAN-Norfolk consortium (2026). Long-term outcomes of drug-coated balloons vs. drug-eluting stents in coronary chronic total occlusion angioplasty: the SPARTAN-CTO study. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-02852-3
Vancouver
Natarajan R, Corballis N, Merinopoulos I, Gunawardena T, Wickramarachchi U, Clark A, et al. Long-term outcomes of drug-coated balloons vs. drug-eluting stents in coronary chronic total occlusion angioplasty: the SPARTAN-CTO study. Clinical Research in Cardiology. 2026. doi:10.1007/s00392-026-02852-3
BibTeX
@article{Natarajan2026,
author = {Natarajan, Rajkumar and Corballis, Natasha and Merinopoulos, Ioannis and Gunawardena, Tharusha and Wickramarachchi, Upul and Clark, Allan and Vassiliou, Vassilios S and Eccleshall, Simon C and SPARTAN-Norfolk consortium, SPARTAN-Norfolk consortium},
title = {Long-term outcomes of drug-coated balloons vs. drug-eluting stents in coronary chronic total occlusion angioplasty: the SPARTAN-CTO study},
journal = {Clinical Research in Cardiology},
year = {2026},
doi = {10.1007/s00392-026-02852-3}
}
EUVIMED